, (GLOBE NEWSWIRE) -- (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today is pleased to announce the appointment of as Executive Chairman, . Mr. Daly is a biopharmaceutical executive with over 30 years of experience leading U.S. and global businesses.

'We are extremely pleased to welcome Jim to the Coherus team,' said , President and Chief Executive Officer of Coherus. 'He is an accomplished commercial executive with a stellar track record who brings a wealth of experience, insight and leadership to address key issues as we build our commercial capabilities. Over the course of his career, Jim has created market-leading global franchises across multiple therapeutic categories, most recently in oncology and inflammation. With CHS-1701 (biosimilar pegfilgrastim), our lead oncology asset, successfully meeting both primary endpoints in its antigenicity registration study and the Biologics License Application (BLA) filing approaching, we are excited to benefit from Jim's knowledge and expertise.'

Mr. Daly will lead the and advise the organization on key strategic commercial issues related to sales, marketing, pricing, contracting, channel strategy development, new product planning and business development.

'I am excited to join Coherus,' said Mr. Daly. 'The team is comprised of individuals who helped pioneer the biotech industry. They have joined together and are driven by a common mission to bring the benefits of breakthrough biologics to more patients in more markets. CHS-1701 is a key asset in the Coherus oncology franchise, and we believe it will pave the way for additional follow on biosimilars in this therapeutic area, unlocking the oncology market potential. It's important for patients, providers, payers as well as for the healthcare system as a whole that high quality biosimilar therapeutics achieve their full potential to expand access and control costs.'

Mr. Daly previously served as Executive Vice President and Chief Commercial Officer at from 2012 to 2015. Prior to , Mr. Daly worked for for 10 years, holding multiple leadership positions. In his last role, Mr. Daly served as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. His teams at were responsible for the successful commercialization of many biologics, including Neulasta®, Enbrel®, Aranesp®, Vectibix®, Nplate®, Xgeva® and Prolia®. Previously, Mr. Daly spent over 16 years with GlaxoSmithKline, where he held roles of increasing responsibility, including Senior Vice President, General Manager of the Respiratory and Anti-Infective Division, and led the U.S. launch of Advair®. He currently serves on the Boards of Directors of and . Jim earned both his M.B.A. and B.S. in Pharmacy from the State of at Buffalo.

About

Coherus is a leading pure-play global biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products. For additional information, please visit www.coherus.com.

Neulasta®, Enbrel®, Aranesp®, Vectibix®, Nplate®, Xgeva® and Prolia® are registered trademarks of Advair® is a registered trademark of . 


INVESTOR AND MEDIA CONTACT:
, M.D.
Investor Relations
kvendola@coherus.com
+1 (650) 437-6239

Coherus BioSciences Inc. issued this content on 01 February 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 01 February 2016 21:37:12 UTC

Original Document: http://investors.coherus.com/phoenix.zhtml?c=253655&p=irol-newsArticle&ID=2134414